CB Therapeutics Targets Psychedelics & Cannabis Markets
Ryan Allway
October 13th, 2020
App, Exclusive, Psychedelics, Top Story
There’s little question that the market for cannabinoids and psychedelics are poised to experience significant growth over the coming years. While the demand for cannabinoids, like cannabidiol (CBD), has already seen tremendous growth, psychedelics represent a blue-sky market due to the potential to treat a wide range of mental health disorders.
Let’s take a look at CB Therapeutics’ unique business model and how it could generate near-term revenue for shareholders in both cannabinoid and psychedelic markets.
Large End Markets
The United States spends over $200 billion each year on mental health disorders, including anxiety, depression, post-traumatic stress disorder and addiction. A growing body of research suggests that psychedelics could play a significant role in addressing these mental health disorders, creating a market that could be worth nearly $7 billion by 2027.
With a growing number of jurisdictions legalizing medical and adult-use cannabis, the market for cannabinoids has also become one of the world’s fastest growing markets. Fortune Business Insights™ projects that the market will reach nearly $100 billion by 2026, driven by growing demand for everything from cannabidiol (CBD) to tetrahydrocannabinol (THC).
CB Therapeutics process vs. other forms of production:
These multi-billion-dollar markets are plant or fungi-based markets that have conventionally relied on cultivation and extraction—expensive and wasteful processes. For instance, ethanol and other byproducts of the cannabis extraction process are often considered “industrial waste” while indoor cannabis cultivation has become a major source of electricity consumption.
Fortunately, CB Therapeutics has been pioneering a flexible yeast-based production platform that reduces costs, increases purity, cuts waste, and shortens the production cycle.
Click here to receive an investor presentation and corporate updates
Near-term Revenue
Many psychedelic companies are conducting clinical trials that will take years to generate meaningful revenue beyond milestone payments. While a handful of companies are focused on non-clinical revenue, these markets remain modest in size and will take time to develop as psychedelics move from the obscure to the mainstream.
CB Therapeutics’ presence in both psychedelics and cannabis puts it into a position to generate millions of dollars in near-term sales of cannabinoids, and after it secures a bulk manufacturing license from the DEA, tryptamines. In fact, the company has already signed a MOU with a leading U.S. academic medical center specializing in clinical trials and research and development to provide a supply of tryptamines for clinical trials.
In addition to the near-term sale of natural molecules and analogs, the company plans to retain the blue-sky potential that many clinically focused companies enjoy by developing novel molecules and their analogs. These molecules can be licensed out to commercialization partners, which could open the door to high margin recurring revenue from royalties.
Click here to receive an investor presentation and corporate updates
Unique Business Model
Many cannabinoid and tryptamine manufacturers either start with plants and fungi that undergo an extraction process or are chemically synthesized. Either way, these manufacturing processes result in both high costs and significant waste.
CB Therapeutics has developed a yeast-based manufacturing process that cuts the cost of production by 20X to 100X and yields minimal waste. In addition, the platform is capable of producing a wide range of cannabinoids or tryptamines at scale that meet high quality control standards to clinical trials or consumer sales.
The business model is supported by a robust intellectual property portfolio that already consists of two granted patents and over a dozen patents pending across the entire value chain, including microorganism, fermentation, purification, products and more.
Located in Carlsbad, CA, the company has a 7,000 sq ft production facility and is run by a seasoned management team and scientists. CB Therapeutics also plans to patent novel molecules that it develops along the way for external licensing.
Click here to receive an investor presentation and corporate updates
Looking Ahead
CB Therapeutics is well positioned to capitalize on both the cannabinoid and psychedelic markets with a unique business model that provides both near-term revenue and long-term blue-sky potential.
The company’s management team has raised US$6.2 million to date, and is looking to raise it’s Series A, to scale its current production and facility from 7,000 sq. ft. in Carlsbad, CA to meet growing demand across its end markets.
Investors interested in these high-growth markets may want to take a closer look at CB Therapeutics as it gears up to go public in the near-term.
For more information, visit the company’s website or download their investor presentation.
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
CaniBrands is a next-generation wellness products company that specializes in manufacturing innovative CBD (Cannabidiol) formulations for sports recovery and active living. CaniBrands products are trusted by professional athletes and backed by science. The company has a wide selection of products for sports recovery, energy, focus, pain and sleep. Along with sublingual oils, balms and creams, […]
Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
